Anika Therapeutics (ANIK) Tops Q2 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.79 --0%
EPS Growth %: +950.0%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
TFS, PBNK, FNRN, More
EPS Growth %: +950.0%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
TFS, PBNK, FNRN, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.68, $0.35 better than the analyst estimate of $0.33. Revenue for the quarter came in at $30.5 million versus the consensus estimate of $27.9 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TFS Financial (TFSL) Reports In-Line Q4 EPS
- Centerra Gold Inc. (CGAU) Reports In-Line Q3 EPS
- Starz Entertainment Corp. (STRZ) Reports Q3 Loss of $2.02
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
